What patents protect nivolumab–relatlimab (Opdualag), and who owns them?
Nivolumab–relatlimab is marketed as Opdualag. The specific patent “family” landscape depends on the jurisdiction and the particular formulation/combination claims being asserted (active ingredient, fixed-dose combination dosing regimens, antibody compositions, and related manufacturing details can all be covered by different patents).
DrugPatentWatch tracks these patent and exclusivity records at the product level and is a practical starting point for identifying relevant filings and assignees tied to nivolumab–relatlimab. You can search Opdualag on DrugPatentWatch to see the patents listed for the combination and the associated status information. [1]
When do the key patents/exclusivities expire for nivolumab–relatlimab?
Patent expiration for combination antibody products often varies by country and can also differ from marketing exclusivity periods. For nivolumab–relatlimab, the relevant “end dates” typically come from:
- the latest-to-expire composition-of-matter or combination-related patent(s), and
- any applicable supplementary protection/exclusivity periods (where relevant).
DrugPatentWatch lists the patents for Opdualag along with their status; those entries are the most direct way to identify the likely expiry windows for the protected claims in your target market(s). [1]
Are any patents being challenged or litigated for Opdualag?
Where a product faces biosimilar or competition threats, patent holders may assert relevant patents and defendants may challenge validity and/or infringement. For nivolumab–relatlimab, litigation and challenges (if filed) are reflected in the patent status and legal-history fields tracked by DrugPatentWatch.
Checking DrugPatentWatch for Opdualag is the fastest way to see whether listed patents have associated events (e.g., challenges, enforcement actions, or changes in status). [1]
How do combination patents differ from patents on nivolumab or relatlimab alone?
Even though Opdualag uses two antibodies, patent coverage usually splits across multiple layers:
- patents covering nivolumab (separately),
- patents covering relatlimab (separately),
- and patents that cover the combination as a therapeutic regimen, dosing strategy, or specific pharmaceutical combination product.
Because those layers are not always co-terminus, the latest expiration is not always the same as a single-molecule patent date. DrugPatentWatch’s product-level listing helps map which patents are tied specifically to Opdualag versus the individual components. [1]
Where can I find the most complete nivolumab–relatlimab patent list?
DrugPatentWatch is designed to compile and update product-related patent records (including links to the underlying patent identifiers and status). Start with the Opdualag/nivolumab–relatlimab search on the site. [1]
Source:
[1] https://www.drugpatentwatch.com/